TAMPA BAY, Fla. (PRWEB)
September 20, 2021

Today, there are approximately 7,000 rare diseases affecting about 350 million worldwide.(1) That is more than the entire population of the United States. Many of these diseases have no treatments. However, clinical drug and treatment trials stand to prevent much of the immense suffering and death. These trials typically take 5 to 7 years to complete and get a drug or vaccine to market. In contrast, COVID-19 vaccines were developed in a fraction of the usual time – in 5 to 7 months.

Enter Disruptor Dr. Harsha Rajasimha, Founder & CEO of Jeeva Informatics Solutions—who explains to Karla Jo Helms, host of the Disruption Interruption podcast—that if we applied the COVID-19 trial’s timeline to other diseases, many more vaccines and drugs for even rare diseases could begin helping millions who are now suffering. But right now, 88% of drugs that enter into human clinical trials do not get FDA approval because of the lack of evidence, enrollment difficulties, and patient retention.

After losing a child to a rare disease, Dr. Rajasimha and the lack of an early diagnosis that could have been detected at the first trimester, Dr. Rajasimha said, THAT’S IT—I’M DONE WITH THE STATUS QUO—and quit his FDA consulting job, resolving to solve the early diagnosis problem – that much of the delays in trials could be solved via software technology – but that using EMPATHY when approaching patients was essential for bringing in and retaining qualified patients for clinical trials.

Dr. Rajasimha then made it his mission to develop a software as a service solution (SaaS) that brings the thousands of stakeholders into the same space to streamline redundant processes to shorten the timelines to drug and vaccine development and redirect resources to further advancements.

Dr. Rajasimha reveals how:

1.    Money isn’t the barrier prohibiting drugs from coming to market—rather it is finding those who fit the criteria along with their enrollment process and retention.

2.    The biggest problem with clinical trials is the failure to identify the right patient, having them understand and enroll in the trial, and their ability to comply, whether it be due to lack of technology and other logistical problems they encounter.

3.    His company is overcoming researchers’ barriers to collecting accurate data, “white coat” and “parking lot” syndrome with patients are among the logistical problems illustrating the human side of clinical trial skewing results

4.    Jeeva’s software solution centralizes and simplifies the clinical trial processes but also incorporates empathy for patients within the trial to accelerate their recruitment and retention.

Disruption Interruption is the podcast where you’ll hear from today’s biggest Industry Disruptors. Learn what motivated them to bring about change and how they overcome opposition to adoption.

Disruption Interruption can be listened to via the Podbean app, and is available on Apple’s App Store and Google Play.

About Disruption Interruption:

Disruption is happening on an unprecedented scale, impacting all manner of industries— MedTech, Finance, IT, eCommerce, shipping and logistics, and more—and COVID has moved their timelines up a full decade or more. But WHO are these disruptors and when did they say, “THAT’S IT! I’VE HAD IT!”? Time to Disrupt and Interrupt with host Karla Jo “KJ” Helms, veteran communications disruptor. KJ interviews bad asses who are disrupting their industries and altering economic networks that have become antiquated with an establishment resistant to progress. She delves into uncovering secrets from industry rebels and quiet revolutionaries that uncover common traits—and not-so-common—that are changing our economic markets… and lives. Visit the world’s key pioneers that persist to success, despite arrows in their backs at http://www.disruptioninterruption.com.

About Karla Jo Helms:

Karla Jo Helms is the Chief Evangelist and Anti-PR(TM) Strategist for JOTO PR Disruptors(TM).

Karla Jo learned firsthand how unforgiving business can be when millions of dollars are on the line—and how the control of public opinion often determines whether one company is happily chosen, or another is brutally rejected. Being an alumni of crisis management, Karla Jo has worked with litigation attorneys, private investigators and the media to help restore companies of goodwill back into the good graces of public opinion—Karla Jo operates on the ethic of getting it right the first time, not relying on second chances and doing what it takes to excel. Helms speaks globally on public relations, how the PR industry itself has lost its way and how, in the right hands, corporations can harness the power of Anti-PR to drive markets and impact market perception.

About Jeeva Informatics:

Jeeva Informatics Solutions, Inc., based out of Tysons Corner, VA, partners with Biopharmaceutical sponsors, CROs, and clinical researchers to accelerate clinical studies. The Jeeva TRIALMAGNET(TM) package of the patent pending Jeeva eClinical Cloud platform achieves remote patient recruitment goals by as much as three times faster. Jeeva’s flexible bring your own device (BYOD) SaaS solution works on any browser-enabled mobile device and saves more than 70% time by minimizing logistical burden on study teams and patients. Modular software design allows a rapid study configuration with the features and workflows that fit the specific trial protocol whether short-term or long-term, cross-sectional or longitudinal, interventional or observational studies, clinical phase or post-market, hybrid or fully remote. To learn more, visit jeevatrials.com.

1.    Ornskov, Flemming. “350 million people suffer from rare diseases. Here’s how tech can help.” World Economic Forum, 19 January 2018, weforum.org/agenda/2018/01/350-million-people-suffer-from-rare-diseases-heres-how-tech-can-help/

Share article on social media or email: